Abstract
Bispecific antibodies with binding specificities for two different antigens have prompted a lot of interest into their development and application. Currently, more than ten bispecific antibodies have been clinically validated for the treatment of various diseases, including cancers and inflammatory diseases. Intensive studies in antibody engineering drive the generation of different bispecific antibody formats that differ in size and shape. However, the most prominent formats, such as IgG-single-chain (sc) Fv or dual-variable domain (DVD) IgG, deviating from the natural IgG structure, may lead to manufacturing difficulties or increase the potential risk of immunogenicity. Thus, the recent efforts focus on the development of bispecific antibodies by Fc heterodimerization that maintain the native structure of the antibody IgG molecule. This review summarizes the various techniques and methods to generate bispecific antibody molecules with Fc heterodimerization, and discusses perspectives of their application.
Keywords: Bispecific antibody, Fc heterodimerization, quadroma, Knobs-into-holes, strand-exchange engineered domain.
Current Pharmaceutical Biotechnology
Title:Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Volume: 17 Issue: 15
Author(s): Zhizhen Chen, Liping Wang, Tianshu Xu, Qifei Wang, Lishan Kang and Qi Zhao
Affiliation:
Keywords: Bispecific antibody, Fc heterodimerization, quadroma, Knobs-into-holes, strand-exchange engineered domain.
Abstract: Bispecific antibodies with binding specificities for two different antigens have prompted a lot of interest into their development and application. Currently, more than ten bispecific antibodies have been clinically validated for the treatment of various diseases, including cancers and inflammatory diseases. Intensive studies in antibody engineering drive the generation of different bispecific antibody formats that differ in size and shape. However, the most prominent formats, such as IgG-single-chain (sc) Fv or dual-variable domain (DVD) IgG, deviating from the natural IgG structure, may lead to manufacturing difficulties or increase the potential risk of immunogenicity. Thus, the recent efforts focus on the development of bispecific antibodies by Fc heterodimerization that maintain the native structure of the antibody IgG molecule. This review summarizes the various techniques and methods to generate bispecific antibody molecules with Fc heterodimerization, and discusses perspectives of their application.
Export Options
About this article
Cite this article as:
Chen Zhizhen, Wang Liping, Xu Tianshu, Wang Qifei, Kang Lishan and Zhao Qi, Generation of Bispecific Antibodies by Fc Heterodimerization and their Application, Current Pharmaceutical Biotechnology 2016; 17 (15) . https://dx.doi.org/10.2174/1389201017666161018150553
DOI https://dx.doi.org/10.2174/1389201017666161018150553 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Features of Carcinosarcoma Arising from Adenofibroma of the Uterus: A Case Report
Current Medical Imaging Molecular Components of Wnt/β-catenin Pathway As Therapeutic Targets For Upper Gastrointestinal Cancers
Clinical Cancer Drugs Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy
Current Drug Targets Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins
Protein & Peptide Letters Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology MicroRNA Dysregulation in Esophageal Neoplasia: The Biological Rationale for Novel Therapeutic Options
Current Pharmaceutical Design Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Clinical Cancer Drugs NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Dual Nuclear/Fluorescence Imaging Potantial of Zinc(II) Phthalocyanine in MIA PaCa-2 Cell Line
Current Radiopharmaceuticals Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets